Given the slightly reduced responsiveness of a-TEA-LS + aPD-L1 ICB in the 4T1 model, we explored the therapeutic efficacy of this combination therapy in two additional tumor models, Eph4 1424 (MEK1-driven) and the PyMT-MMTV Tg model of spontaneously arising mammary carcinoma. This evidence concerns the gene MAP2K1 and breast carcinoma.